BiotechTube
Orbus Therapeutics

Orbus Therapeutics

Palo Alto, United States· Est.
orbustherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $42M

Overview

Orbus Therapeutics is a private, pre-revenue biotech founded in 2004 and headquartered in Palo Alto, California. The company's sole clinical asset is eflornithine, which recently completed its pivotal Phase 3 STELLAR trial in 2024 for the treatment of anaplastic astrocytoma, a rare brain tumor. With a seasoned leadership team experienced in CNS and oncology drug development, Orbus is positioned to potentially bring a new treatment option to a patient population with very limited effective therapies. The company's near-term future hinges on the results and regulatory review of the STELLAR study.

OncologyRare Diseases

Technology Platform

Focused development of the small molecule eflornithine, an ornithine decarboxylase (ODC) inhibitor, for a specific rare oncology indication.

Funding History

2
Total raised:$42M
Series B$30M
Series A$12M

Opportunities

Positive results from the Phase 3 STELLAR trial could establish eflornithine as a new standard of care maintenance therapy for a rare brain cancer with high unmet need, enabling regulatory approval and orphan drug commercialization.
The company's focused rare disease strategy allows for potential premium pricing and regulatory incentives like orphan drug exclusivity.

Risk Factors

The company faces extreme binary risk as its entire value depends on the success of a single Phase 3 trial; failure would be catastrophic.
As a pre-revenue, private company, it also carries significant financial and execution risk in navigating regulatory submission and building commercial capabilities.

Competitive Landscape

The competitive landscape for anaplastic astrocytoma is characterized by a lack of approved maintenance therapies, representing a significant unmet need. However, the broader neuro-oncology field is active with investigational targeted therapies and immunotherapies that could eventually impact this patient segment.

More companies in Small Molecule Drugs →More companies in United States →